Suren Dutia Net Worth

Suren Dutia biography

Suren G. Dutia serves as Independent Director of the Company. Mr. Dutia has been a member of the Board since October 2015. Mr. Dutiahas served as Senior Fellow of the Ewing Mario Kauffman Foundation since March 2011 and as Senior Fellow of Skandalaris Center for Entrepreneurial Studies at Washington University, St. Louis since 2013. He has served as a member of the advisory board of Center for Digital Transformation, University of California, Irvine since May 2012 and as chairman of the board of directors of AccelPath, LLC since October 2009. From February 2006 to May 2010, Mr. Dutia served as the Chief Executive Officer of TiE Global, a non-profit organization involved in globally fostering entrepreneurship. From February 2011 to May 2013, Mr. Dutia served as a director of LifeProof Cases and from July 2000 to December 2011, he served as a director of Anvita Health. From 1989 to 1998, Mr. Dutia served as the Chief Executive Officer and chairman of the board of directors of Xscribe Corporation. Prior to his positions with Xscibe Corporation, Mr. Dutia held several positions with Dynatech Corporation, and in addition, he was the president of a medical instruments company. Previously, Mr. Dutia worked for the U.S. Department of Education. Mr. Dutia received his B.S. and M.S. degrees in chemical engineering and B.A. in political science from Washington University, St. Louis. In addition, he obtained an M.B.A. from University of Dallas.

How old is Suren Dutia?

Suren Dutia is 77, he's been the Independent Director of Citius Pharmaceuticals Inc since 2015. There are no older and 13 younger executives at Citius Pharmaceuticals Inc.

What's Suren Dutia's mailing address?

Suren's mailing address filed with the SEC is C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ, 07016.

Insiders trading at Citius Pharmaceuticals Inc

Over the last 9 years, insiders at Citius Pharmaceuticals Inc have traded over 0$ worth of Citius Pharmaceuticals Inc stock and bought 13,825,289 units worth 15,819,221$ . The most active insiders traders include Leonard L Mazur、Myron Z Holubiak、Dennis M Mcgrath. On average, Citius Pharmaceuticals Inc executives and independent directors trade stock every 207 days with the average trade being worth of 523,934$. The most recent stock trade was executed by Eugene Myron Holuka on 13 March 2024, trading 2,415 units of CTXR stock currently worth 48$.

What does Citius Pharmaceuticals Inc do?

citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.

Citius Pharmaceuticals Inc executives and stock owners

Citius Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Myron Z. Holubiak,
  Pres, CEO & Director
• Myron Holubiak,
  President, Chief Executive Officer, Director
• Leonard L. Mazur,
  Exec. Chairman & Sec.
• Dr. Myron S. Czuczman M.D.,
  Exec. VP & Chief Medical Officer
• Jaime Bartushak,
  Chief Financial Officer, Principal Financial Officer
• Jaime Bartushak,
  CFO & Chief Accounting Officer
• Leonard Mazur,
  Executive Chairman of the Board, Secretary
• Carol Webb,
  Independent Director
• Howard Safir,
  Independent Director
• William Kane,
  Independent Director
• Eugene Holuka,
  Independent Director
• Suren Dutia,
  Independent Director
• Kelly Creighton Ph.D.,
  Exec. VP of Chemistry, Manufacturing & Controls
• Dhananjay G. Wadekar,
  Sr. VP of Bus. Strategy
• Ilanit Allen,
  VP of Investor Relations
• Gary F. Talarico,
  Exec. VP of Operations
• Myron Czuczman,
  Chief Medical Officer
• Robert Joseph Smith,
  Director
• Dennis M Mcgrath,
  Director